The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Aroa Biosurgery Limited (ASX:ARX) shareholders over the last year, as the share price declined 43%. That contrasts poorly with the market return of 9.6%. Aroa Biosurgery may have better days ahead, of course; we've only looked at a one year period. The falls have accelerated recently, with the share price down 41% in the last three months.

If the past week is anything to go by, investor sentiment for Aroa Biosurgery isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

Check out our latest analysis for Aroa Biosurgery

Because Aroa Biosurgery made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Aroa Biosurgery grew its revenue by 47% over the last year. That's well above most other pre-profit companies. Given the revenue growth, the share price drop of 43% seems quite harsh. Our sympathies to shareholders who are now underwater. On the bright side, if this company is moving profits in the right direction, top-line growth like that could be an opportunity. Our monkey brains haven't evolved to think exponentially, so humans do tend to underestimate companies that have exponential growth.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). earnings-and-revenue-growth

Take a more thorough look at Aroa Biosurgery's financial health with this freereport on its balance sheet.

A Different Perspective

While Aroa Biosurgery shareholders are down 43% for the year, the market itself is up 9.6%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. The share price decline has continued throughout the most recent three months, down 41%, suggesting an absence of enthusiasm from investors. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. It's always interesting to track share price performance over the longer term. But to understand Aroa Biosurgery better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted  2 warning signs for Aroa Biosurgery  you should know about.



If you are like me, then you will not want to miss this freelist of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.